Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare

3. Abbott Laboratories (NYSE:ABT)

Number of Hedge Fund Holders In Q3 2024: 63

Abbott Laboratories (NYSE:ABT) is a healthcare giant that ended 2024 on a tepid note. Its shares gained a modest 3.8% during the year as the firm battled the fallout from its infant formula lawsuit through mostly strong earnings reports because of its medical devices business. Like other mega American healthcare companies, Abbott Laboratories (NYSE:ABT) is facing tightness in China. However, in his previous remarks, Cramer has been optimistic about the firm’s diabetes portfolio which includes glucose monitoring devices. The optimism was warranted as Abbott Laboratories (NYSE:ABT)’s shares have gained 10% since its Q4 earnings came with a midpoint 2025 profit per share guidance of $5.15 which was in line with estimates. Cramer was surprised about Abbott Laboratories (NYSE:ABT)’s share surge:

“Abbot Labs was the market leader yesterday. That’s new. That’s new.”